What is the role of eribulin (Halaven) in the treatment of liposarcoma?

Updated: Mar 18, 2020
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

In January 2016, eribulin (Halaven), a microtubule inhibitor, [39]  was approved by the US Food and Drug Administration (FDA) for unresectable or metastatic liposarcoma in patients who received a prior anthracycline-containing regimen. The FDA approval is based on the results from the subgroup of 143 patients with liposarcoma. In this subgroup, the results show a 7-month improvement in survival (15.6 months with eribulin compared with 8.4 months with dacarbazine). The median progression-free survival, a secondary endpoint, was 2.9 months with eribulin compared with 1.7 months with dacarbazine. However, eribulin was more toxic than dacarbazine. Treatment-emergent adverse events included neutropenia (44% vs 24%), pyrexia (28% vs 14%), peripheral sensory neuropathy (20% vs 4%), and alopecia (35% vs 3%) for eribulin compared with dacarbazine, respectively. [40]

Comprehensive genomic profiling may facilitate targeted therapy for individual liposarcomas in the future. [41]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!